Form 4: Aligos Therapeutics Grants Stock Options to COO and CFO Lesley Ann Calhoun

Aligos Therapeutics, Inc. has granted 40,185 stock options to its Chief Operating Officer and Chief Financial Officer, Lesley Ann Calhoun, with an exercise price of $8.68 per share.

Summary

• Lesley Ann Calhoun, Chief Operating Officer and Chief Financial Officer of Aligos Therapeutics, Inc. (ALGS), was granted 40,185 stock options.
• The options have an exercise price of $8.68 per share.
• The grant date for these options was July 16, 2025.
• The options will vest in 48 equal monthly installments, starting from July 16, 2025, over a four-year period.
• Full vesting is contingent upon Ms. Calhoun's continued service to the company.
• The options expire on July 16, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is a positive sign of executive retention and alignment with shareholder interests, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of stock options aligns the interests of the Chief Operating Officer and Chief Financial Officer, Lesley Ann Calhoun, with those of shareholders, incentivizing long-term company performance.
• The vesting schedule over four years encourages retention of key executive talent.

Negatives

• The issuance of new stock options could lead to potential dilution for existing shareholders if the options are exercised in the future, although this is a standard component of executive compensation.

Risks

• No specific new risks are introduced by this Form 4 filing beyond the general risk of dilution inherent in stock option grants, which is a standard compensation practice.

Future Outlook

The vesting schedule indicates a forward-looking incentive structure for executive retention and performance over the next four years, aligning executive interests with long-term company growth.

Industry Context

Executive stock option grants are a common form of compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key talent by linking their financial success to the company's stock performance. This grant is consistent with standard industry practices for executive compensation.

Comparison to Industry Standards

• The grant of stock options to a senior executive like the COO/CFO is a standard practice across the biotechnology and broader corporate sectors for executive compensation.
• The four-year vesting schedule is typical for long-term incentive plans, comparable to those seen at companies like Moderna (MRNA) or BioNTech (BNTX) for their executive teams, aiming to ensure long-term commitment and performance alignment.
• The exercise price of $8.68 is likely based on the market price of Aligos Therapeutics' stock on the grant date, which is a common method for setting option prices to ensure they are "at-the-money" or "out-of-the-money" at the time of grant.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from incentivized executive performance.
• Employees: May signal stability in executive leadership and a standard approach to executive compensation.
• Management (Lesley Ann Calhoun): Receives a significant long-term incentive tied to the company's stock performance.

Next Steps

• Continued service of Lesley Ann Calhoun to Aligos Therapeutics, Inc. to fulfill vesting conditions.
• Monthly vesting of 1/48th of the granted stock options over the next four years, starting July 16, 2025.

Key Dates

Recommendation

Keywords

Aligos Therapeutics, ALGS, Stock Option Grant, SEC Form 4, Insider Transaction, Executive Compensation, Lesley Ann Calhoun, COO, CFO, Equity Compensation